Bank of America has adjusted its price target for Apellis Pharmaceuticals (APLS, Financial), bringing it down to $41 from the previous $44. Despite this revision, the investment firm continues to maintain its Buy rating on the stock.
This update comes as part of a comprehensive review of small and mid-cap biotechnology firms conducted in anticipation of their first-quarter earnings reports. Apellis has remained a focal point due to its potential within the biotech sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 19 analysts, the average target price for Apellis Pharmaceuticals Inc (APLS, Financial) is $42.26 with a high estimate of $75.00 and a low estimate of $22.00. The average target implies an upside of 132.22% from the current price of $18.20. More detailed estimate data can be found on the Apellis Pharmaceuticals Inc (APLS) Forecast page.
Based on the consensus recommendation from 22 brokerage firms, Apellis Pharmaceuticals Inc's (APLS, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Apellis Pharmaceuticals Inc (APLS, Financial) in one year is $223.82, suggesting a upside of 1129.78% from the current price of $18.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Apellis Pharmaceuticals Inc (APLS) Summary page.
